Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy

The aim of this study was to investigate the effect of rituximab (RTX) treatment on serum immunoglobulin (Ig) A, G, M levels, and B and CD4+CD25+FoxP3+ [T regulatory (Treg)] cell numbers in children who received RTX therapy with steroid-resistant nephrotic syndrome (SRNS). Twenty-three SRNS children...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of kidney diseases and transplantation 2021-07, Vol.32 (4), p.1028-1033
Main Authors: Tunçay, Seçil, Hakverdi, Gülden, Şenol, Özgür, Mir, Sevgi
Format: Article
Language:English
Subjects:
Care and treatment
Cross-Sectional Studies
Humans
Immunoglobulin A
Immunoglobulin G
Immunotherapy
Kidney diseases
Monoclonal antibodies
Nephrotic syndrome
Nephrotic Syndrome - diagnosis
Nephrotic Syndrome - drug therapy
Rituximab - adverse effects
Steroids
Steroids - therapeutic use
T cells
T-Lymphocytes, Regulatory
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate the effect of rituximab (RTX) treatment on serum immunoglobulin (Ig) A, G, M levels, and B and CD4+CD25+FoxP3+ [T regulatory (Treg)] cell numbers in children who received RTX therapy with steroid-resistant nephrotic syndrome (SRNS). Twenty-three SRNS children who received RTX and 20 healthy children in the control group were included. In this cross-sectional cohort study, 23 children with SRNS levels were determined before and one month after RTX treatment by serum IgA, IgG, IgM, and percentages of CD4+CD25+ FoxP3+ cells and B CD19+ cells by flow cytometry (FASCalibur). RTX was administered at a total of four doses of 375 mg/m2/week. Before RTX treatment, percentages of Treg and IgG values were significantly lower in the SRNS group compared to the control group, respectively (P = 0.001). B-cells were significantly lower one month after RTX treatment than before RTX treatment, respectively (P = 0.001). One month after RTX treatment percentages of Tregs, it was found to be significantly higher than before treatment level (P = 0.001). Seventy percent (11/23) remission was achieved with RTX treatment. RTX treatment not only depletes the number of B-cells in SRNS patients but also causes an increase in the number of percentages of Treg cells.
ISSN:1319-2442
2320-3838
DOI:10.4103/1319-2442.338276